Page 7 - மேற்பரப்பு புற்றுநோயியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மேற்பரப்பு புற்றுநோயியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மேற்பரப்பு புற்றுநோயியல் Today - Breaking & Trending Today

Mad Money Recap With Jim Cramer: A Plan for Earnings Season

Mad Money Recap With Jim Cramer: A Plan for Earnings Season
TheStreet
1/16/2021
© TheStreet
Mad Money Recap With Jim Cramer: A Plan for Earnings Season
It s always difficult to navigate earnings season, Jim Cramer told his Mad Money viewers Friday, but there are opportunities out there if you know where to look.
Cramer s game plan for next week s action begins on Tuesday, after the long holiday weekend. He expects great earnings from Goldman Sachs but said Bank of America will be hard pressed to impress Wall Street. He still liked Netflix , but said streaming fatigue is beginning to set in, making Roku a better play. ....

United States , North Carolina , Jim Cramer , Matt Ehrlichman , Dave Girouard , Crown Castle , United Airlines , Morgan Stanley , Porch Group , Taiwan Semiconductor , Goldman Sachs , Union Pacific , Opko Health , Federal Reserve , Unitedhealth Group , Ford Motor , Procter Gamble , Skyworks Solutions , Mad Money Recap With Jim Cramer , Earnings Season , Mad Money , Action Alerts , Marvell Technologies , Real Money , Upstart Holdings , Lightning Round ,

GSK signs collaboration deal with Ligand targeting neurological disorders

GSK signs collaboration deal with Ligand targeting neurological disorders
This is the latest in a string of pipeline deals announced by GSK
GlaxoSmithKline (GSK) has signed a collaboration and licence agreement with Ligand Pharmaceuticals’ subsidiary Icagen to develop small molecule therapeutics targeting neurological diseases.
The deal will leverage Icagen’s expertise in small molecule therapeutics targeting transmembrane proteins, utilising the company’s discovery technology to identify and develop inhibitors of a ‘specific genetically-validated molecular target’ relevant to neurological diseases.
GSK will pay Ligand an upfront payment of $7m to access its expertise and technology, with additional development, regulatory and commercialisation milestone payments of up to $154.5m. ....

United Kingdom , John Lepore , Sosei Heptares , Ligand Pharmaceutical , Surface Oncology , United Kingdom Based , ஒன்றுபட்டது கிஂக்டம் , ஜான் தொழுநோய் , மேற்பரப்பு புற்றுநோயியல் , ஒன்றுபட்டது கிஂக்டம் அடிப்படையிலானது ,

GlaxoSmithKline gets booster from £100m drug deals spree

Pharma giant GlaxoSmithKline is this week set to cap a £100million spending spree with two major drug deals either side of the Atlantic, The Mail on Sunday can reveal.
Chief executive Emma Walmsley is poised to sign an agreement with a UK biotechnology company that will give GSK exclusive access to a promising early-stage treatment for immune disorders that affect millions of people worldwide.
Separately, the FTSE 100 firm is closing in on a deal with another US biotech company to discover and develop potential drugs for neurological disorders.
Expansion: The arrangements will bolster GlaxoSmithKline boss Emma Walmsley s plan to build a pipeline of new drugs ....

United Kingdom , United States , Emma Walmsley , Steve Jackson , Surface Oncology , Professor Steve , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் , எம்மா வால்ம்ஸ்லி , ஸ்டீவ் ஜாக்சன் , மேற்பரப்பு புற்றுநோயியல் , ப்ரொஃபெஸர் ஸ்டீவ் ,

BioSpace Movers & Shakers, Dec. 18

Published: Dec 18, 2020
By Alex Keown
Cidara Therapeutics – Christopher Kurtz was named executive vice president of Technical Operations at Cidara Therapeutics. Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Prior to joining Cidara, Kurtz served as head of commercial API manufacturing at Gilead Sciences. He previously served as vice president, for drug device industrialization at AbbVie, where he led product scale-up and industrialization projects for drug-device combinations. Prior to that, Kurtz held a number of leadership positions at various companies, including Monsanto, Nektar Therapeutics, Alza Corporation, Alexza and Novo Nordisk. ....

New York , United States , Rockefeller University , United Kingdom , Terri Gaskell , Peter Greenleaf , Scott Burger , Andrea Heslin Smiley , Eli Lilly , Jeffrey Vacira , Manny Triggiano , Dmitri Daveynis , Michael Weinblatt , N Manisha Shetty Gulati , Mervyn Turner , Sandip Kapadia , D Martin Carter , Djordje Filipovic , Perry Calias , Siemens Healthineers , Marylyn Rigby , Daphne Karydas , Badreddin Edris , David Enloe , Jeff Myers , Stanley Cohen ,

GSK pays $85m upfront for Surface Oncology's lead cancer drug

GSK pays $85m upfront for Surface Oncology’s lead cancer drug
British pharma company adds preclinical antibody to its pipeline
GlaxoSmithKline (GSK) has added a preclinical oncology asset to its pipeline after paying $85m upfront for Surface Oncology’s lead asset.
The preclinical programme includes SRF813, a fully human IgG1 antibody targeting PVRIG – an inhibitory protein expressed on natural killer cells (NK cells) and T cells.
SRF813 binds to a distinct epitope on PVRIG and blocks the interaction between this protein and CD112, its binding partner that is over-expressed on tumour cells.
According to Surface, in preclinical studies SRF813 was found to promote the activation of both NK cells and T cells, which it says reflects a potential to produce strong anti-tumour responses and promote immunological memory. ....

Jeff Goater , Axel Hoos , Merck Co , Surface Oncology , மெர்க் இணை , மேற்பரப்பு புற்றுநோயியல் ,